GARAŽA forum

brabonjak napisao: 26 Jan 2022, 14:56

Heinz napisao: 26 Jan 2022, 10:52 Kažu neki da se omikron najčešće i kači na već preležale. A tako je nekako i ovde u firmi.

Omikron se najčešće kači na dvostruko vakcinisane pa potom na nevakcinisane. Booster-ovani i preležani se drže mnogo bolje.

Kabe napisao: 26 Jan 2022, 16:32 Jeste, pričao mi drugar jeo pitu mnogo je slatka...

The rates of myocarditis were highest after the second vaccination dose in adolescent males aged 12 to 15 years (70.7 per million doses of the BNT162b2 vaccine), in adolescent males aged 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine), and in young men aged 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively). There were 826 cases of myocarditis among those younger than 30 years of age who had detailed clinical information available; of these cases, 792 of 809 (98%) had elevated troponin levels, 569 of 794 (72%) had abnormal electrocardiogram results, and 223 of 312 (72%) had abnormal cardiac magnetic resonance imaging results. Approximately 96% of persons (784/813) were hospitalized and 87% (577/661) of these had resolution of presenting symptoms by hospital discharge. The most common treatment was nonsteroidal anti-inflammatory drugs (589/676; 87%).

Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men. This risk should be considered in the context of the benefits of COVID-19 vaccination.